白细胞介素-10 在癌症免疫治疗中的作用：从基础到临床。
Interleukin-10 in cancer immunotherapy: from bench to bedside.
机构信息
Developmental Therapeutics Clinic, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.
Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
出版信息
Trends Cancer. 2023 Sep;9(9):716-725. doi: 10.1016/j.trecan.2023.05.003. Epub 2023 Jun 14.
Abstract
Interleukin (IL)-10 was one of the first cytokines to be recognized. However, its functionality in promoting antitumor immunity was described more recently. Context- and concentration-dependent biological effects are the hallmarks of the pleiotropic role of IL-10. Despite reducing tumor-promoting inflammation, IL-10 may have a role in rejuvenating exhausted tumor-resident T cells. Contrary to the assumption that IL-10 produces an immunosuppressive tumor microenvironment (TME), it promotes activation of tumor-resident CD8+ T cells, which aids tumor rejection. Emerging data from published early-Phase trials have shown mixed results in different tumor types. In this review, we summarize the biological effects of IL-10 and highlight the clinical experience using pegilodecakin.
摘要
白细胞介素 (IL)-10 是最早被识别的细胞因子之一。然而，其促进抗肿瘤免疫的功能是最近才被描述的。依赖于上下文和浓度的生物学效应是 IL-10 多效性作用的标志。尽管 IL-10 减少了促进肿瘤的炎症，但它可能在使耗尽的肿瘤驻留 T 细胞恢复活力方面发挥作用。与 IL-10 产生免疫抑制性肿瘤微环境 (TME)的假设相反，它促进肿瘤驻留 CD8+T 细胞的激活，从而有助于肿瘤排斥。已发表的早期临床试验的新数据显示，不同肿瘤类型的结果存在差异。在这篇综述中，我们总结了 IL-10 的生物学效应，并强调了使用培格利单抗的临床经验。
相似文献
1
Interleukin-10 in cancer immunotherapy: from bench to bedside.
Trends Cancer. 2023 Sep;9(9):716-725. doi: 10.1016/j.trecan.2023.05.003. Epub 2023 Jun 14.
2
PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8 T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients.
Cancer Cell. 2018 Nov 12;34(5):775-791.e3. doi: 10.1016/j.ccell.2018.10.007.
3
Pegylated IL-10 induces cancer immunity: the surprising role of IL-10 as a potent inducer of IFN-γ-mediated CD8(+) T cell cytotoxicity.
Bioessays. 2013 Jul;35(7):623-31. doi: 10.1002/bies.201300004. Epub 2013 May 13.
4
Cytokine-based Cancer Immunotherapy: Challenges and Opportunities for IL-10.
Anticancer Res. 2021 Jul;41(7):3247-3252. doi: 10.21873/anticanres.15110. Epub 2021 Jul 5.
5
Pegylated Interleukin-10: Clinical Development of an Immunoregulatory Cytokine for Use in Cancer Therapeutics.
Curr Oncol Rep. 2019 Feb 21;21(2):19. doi: 10.1007/s11912-019-0760-z.
6
Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation.
Theranostics. 2021 May 3;11(14):6668-6681. doi: 10.7150/thno.56494. eCollection 2021.
7
Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy.
Front Immunol. 2018 Dec 18;9:2905. doi: 10.3389/fimmu.2018.02905. eCollection 2018.
8
Unveiling the multifaceted antitumor effects of interleukin 33.
Front Immunol. 2024 May 31;15:1425282. doi: 10.3389/fimmu.2024.1425282. eCollection 2024.
9
PEGylated IL-10: Clinical Development in Cancer Immunotherapy, Where to Go?
Curr Oncol Rep. 2023 Feb;25(2):115-122. doi: 10.1007/s11912-022-01355-4. Epub 2022 Dec 31.
10
IL-10 in cancer: an essential thermostatic regulator between homeostatic immunity and inflammation - a comprehensive review.
Future Oncol. 2022 Sep;18(29):3349-3365. doi: 10.2217/fon-2022-0063. Epub 2022 Sep 29.
引用本文的文献
1
Nanotechnology and natural killer cell immunotherapy: synergistic approaches for precise immune system adjustment and targeted cancer treatment in gastrointestinal tumors.
Front Med (Lausanne). 2025 Aug 21;12:1647737. doi: 10.3389/fmed.2025.1647737. eCollection 2025.
2
Role of the tumor microenvironment in promoting treatment resistance in urothelial carcinoma (Review).
Mol Med Rep. 2025 Nov;32(5). doi: 10.3892/mmr.2025.13658. Epub 2025 Aug 24.
3
Cytokine Regulation and Oxidative Stress in Helicobacter Pylori-Associated Gastric Adenocarcinoma at Different Stages: Insights from a Cross-Sectional Study.
Int J Mol Sci. 2025 Aug 6;26(15):7609. doi: 10.3390/ijms26157609.
4
The efficacy and peripheral blood predictors in recurrent platinum-resistant ovarian cancer patients treated with immune checkpoint inhibitors.
J Ovarian Res. 2025 Aug 7;18(1):175. doi: 10.1186/s13048-025-01755-7.
5
The gut microbiota in cancer immunity and immunotherapy.
Cell Mol Immunol. 2025 Aug 6. doi: 10.1038/s41423-025-01326-2.
6
Cytokine Therapy in Bladder Cancer: Mechanisms, Efficacy, and Future Prospects.
Curr Issues Mol Biol. 2025 Apr 15;47(4):278. doi: 10.3390/cimb47040278.
7
High-precision immune-related plasma proteomics profiling predicts response to immunotherapy in patients with triple-negative breast cancer.
Cancer Biol Med. 2025 Jul 4;22(7):854-70. doi: 10.20892/j.issn.2095-3941.2025.0038.
8
Recent advances in novel tumor immunotherapy strategies based on regulating the tumor microenvironment and immune checkpoints.
Front Immunol. 2025 Jun 18;16:1529403. doi: 10.3389/fimmu.2025.1529403. eCollection 2025.
9
Synergistic Antitumor Effects of Caerin Peptides and Dendritic Cell Vaccines in a 4T-1 Murine Breast Cancer Model.
Vaccines (Basel). 2025 May 28;13(6):577. doi: 10.3390/vaccines13060577.
10
Mechanistic insights curcumin's anti-inflammatory in pancreatic cancer: experimental and computational evidence implicating IL1B interference IL10RA upregulation and NLRP3/TLR3 downregulation.
Front Cell Dev Biol. 2025 Jun 4;13:1601908. doi: 10.3389/fcell.2025.1601908. eCollection 2025.
本文引用的文献
1
Metabolic reprogramming of terminally exhausted CD8 T cells by IL-10 enhances anti-tumor immunity.
Nat Immunol. 2021 Jun;22(6):746-756. doi: 10.1038/s41590-021-00940-2. Epub 2021 May 24.
2
Structure-based decoupling of the pro- and anti-inflammatory functions of interleukin-10.
Science. 2021 Mar 19;371(6535). doi: 10.1126/science.abc8433.
3
Pegilodecakin as monotherapy or in combination with anti-PD-1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I study.
Int J Cancer. 2021 Jul 15;149(2):403-408. doi: 10.1002/ijc.33556. Epub 2021 Mar 24.
4
Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA).
J Clin Oncol. 2021 Apr 1;39(10):1108-1118. doi: 10.1200/JCO.20.02232. Epub 2021 Feb 8.
5
Randomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination With Pegilodecakin in Patients With Metastatic NSCLC (CYPRESS 1 and CYPRESS 2).
J Thorac Oncol. 2021 Feb;16(2):327-333. doi: 10.1016/j.jtho.2020.10.001. Epub 2020 Nov 6.
6
Engineered IL-10 variants elicit potent immunomodulatory effects at low ligand doses.
Sci Signal. 2020 Sep 15;13(649):eabc0653. doi: 10.1126/scisignal.abc0653.
7
Immune regulation and cytotoxic T cell activation of IL-10 agonists - Preclinical and clinical experience.
Semin Immunol. 2019 Aug;44:101325. doi: 10.1016/j.smim.2019.101325. Epub 2019 Nov 6.
8
Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial.
Lancet Oncol. 2019 Nov;20(11):1544-1555. doi: 10.1016/S1470-2045(19)30514-5. Epub 2019 Sep 25.
9
Targeting Tumors with IL-10 Prevents Dendritic Cell-Mediated CD8 T Cell Apoptosis.
Cancer Cell. 2019 Jun 10;35(6):901-915.e4. doi: 10.1016/j.ccell.2019.05.005.
10
Expression of a soluble IL-10 receptor enhances the therapeutic effects of a papillomavirus-associated antitumor vaccine in a murine model.
Cancer Immunol Immunother. 2019 May;68(5):753-763. doi: 10.1007/s00262-018-02297-2. Epub 2019 Feb 26.
Zotero 插件